Meta AnalysisID 7895
补硒对代谢性疾病患者心血管危险因素的影响：随机对照试验的系统评价与Meta分析
CRD42023439196
placebo, blank control;The purpose of this systematic review and meta-analysis was to evaluate the effect of selenium supplementation on cardiovascular risk factors with metabolic diseases. p:metabolic diseases I:seleniu
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7895
- Evidence Id
- 16453
- Core Evidence Id
- 16453
- Source Meta Analysis Id
- 7892
- Herb2 Meta Analysis Id
- HBMA007892
- Crd Id
- CRD42023439196
- Title
- The Effects of Selenium Supplementation on Cardiovascular Risk Factors Among Patients with Metabolic Diseases:A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Review Question
- placebo, blank control;The purpose of this systematic review and meta-analysis was to evaluate the effect of selenium supplementation on cardiovascular risk factors with metabolic diseases. p:metabolic diseases I:selenium supplementation C:placebo, blank control O:Insulin, FPG, QUICKI, HOMA-B, HOMA-IR, blood lipid, hs-CRP, TAC, NO, GSH, Weight, and BMI.
- Study Type Included
- RCTs
- Condition Being Studied
- Metabolic syndrome is a group of clinical syndromes that are characterized by a combination of obesity, hyperglycemia, hypertension, and dyslipidemia. Patients with metabolic syndrome usually have cardiovascular risk factors, including disorders of glucolipid metabolism, inflammatory oxidative stress, and body weight and BMI, and are at high risk for developing cardiovascular disease. Selenium supplementation has been reported to improve cardiovascular risk factors in patients with metabolic diseases.
- Participant
- Metabolic disease-related patients
- Animal
- Human Disease Modelled
- Intervention
- The experimental group received selenium supplementation treatment.
- Comparator Control
- The control group received placebo treatment.
- Main Outcome
- Insulin, FPG, QUICKI, HOMA-B, HOMA-IR Measures of effect The indicators with the same unit was selected mean difference(MD); The standardized mean difference(SMD) was used for the indicators with inconsistent units.
- Outcome Measure
- Additional Outcome
- blood lipid, hs-CRP, TAC, NO, GSH, Weight, BMI Measures of effect The indicators with the same unit was selected mean difference(MD); The standardized mean difference(SMD) was used for the indicators with inconsistent units.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Dietary Supplements; Humans; Insulin; Insulin, Regular, Human; Lipids; Metabolic Diseases; Randomized Controlled Trials as Topic; Risk Factors; Selenium
- Contact
- weixiu qiu [email protected]
- Organisational Affiliation
- Weifang Medical University
- Funding Source
- Weifang Medical University
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-07-10
- Registration Date
- 2023-07-21
- Anticipated Start Date
- 2023-05-21
- Anticipated Completion Date
- 2023-08-10
- Title Cn
- 补硒对代谢性疾病患者心血管危险因素的影响：随机对照试验的系统评价与Meta分析
- Title En
- The Effects of Selenium Supplementation on Cardiovascular Risk Factors Among Patients with Metabolic Diseases:A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Bilingual Status
- complete